文献速递贫血与红细胞疾病

辛伐他汀减少镰状细胞贫血血管闭塞性疼痛:一项先导性疗效试验

Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.
PubMed 文献 · Br J Haematol · 2017-03-28

该先导性疗效试验对19例镰状细胞贫血患者给予每日单次辛伐他汀治疗3个月,评估日记报告的疼痛频率与强度及循环炎症标志物较基线的变化。治疗使疼痛频率(P=0.0003)、口服镇痛药使用(P=0.003)及hs-CRP(P=0.003)、sE-选择素(P=0.01)、sICAM-1(P=0.02)、sICAM-3(P=0.02)、sVEGF(P=0.01)显著降低,对疼痛强度及NOx、sP-选择素、sVCAM-1无影响。接受羟基脲者疼痛频率与炎症标志物下降最明显,提示辛伐他汀可能具有协同效应;结果为先导性临床数据,支持开展更大规模试验。

要点

  • 19例镰状细胞贫血患者每日单次辛伐他汀治疗3个月,疼痛频率较基线显著降低(P=0.0003)。
  • 口服镇痛药使用(P=0.003)及hs-CRP、sE-选择素、sICAM-1、sICAM-3、sVEGF较基线显著降低。
  • 疼痛强度及NOx、sP-选择素、sVCAM-1无变化;接受羟基脲者下降最明显,提示可能协同。

核心结论

  • 辛伐他汀治疗3个月可显著降低镰状细胞贫血患者日记报告的疼痛频率和口服镇痛药使用,并降低多种循环炎症标志物。
  • 疼痛频率与炎症标志物的下降在接受羟基脲者中最明显,提示辛伐他汀可能具有协同效应。
  • 这些结果提供先导性临床数据,支持在镰状细胞贫血中开展更大规模的辛伐他汀试验。

研究设计与样本

  • 先导性疗效试验,对19例镰状细胞贫血患者给予每日单次辛伐他汀治疗3个月。
  • 评估日记报告的疼痛频率与强度及循环NOx、hs-CRP、VCAM-1、ICAM-1、ICAM-3、E-选择素、VEGF较基线的变化。

主要发现

  • 辛伐他汀使疼痛频率显著降低(P=0.0003)、口服镇痛药使用显著降低(P=0.003)。
  • 辛伐他汀使循环hs-CRP(P=0.003)、sE-选择素(P=0.01)、sICAM-1(P=0.02)、sICAM-3(P=0.02)、sVEGF(P=0.01)显著降低。
  • 辛伐他汀对疼痛强度及NOx、sP-选择素、sVCAM-1水平无影响。
  • 疼痛频率和炎症标志物的下降在接受羟基脲(HC)者中最明显,提示辛伐他汀的协同效应。

局限性

  • 原文结论指出这些结果仅为先导性临床数据,支持开展更大规模的辛伐他汀试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell anaemia (SCA) is a progressive vascular disease characterized by episodic vaso-occlusive pain. Despite the broad impact of inflammation on acute and chronic clinical manifestations of SCA, no directed anti-inflammatory therapies currently exist. Statins are cholesterol-lowering agents shown to confer protection from vascular injury by suppressing inflammation. We previously documented a reduction in soluble biomarkers of inflammation in patients with sickle cell disease treated with simvastatin. To determine the potential clinical efficacy of simvastatin, we treated 19 SCA patients with single daily dose simvastatin for 3 months and assessed changes from baseline in the frequency and intensity of diary-reported pain and levels of circulating nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), ICAM-3, E-selectin, and vascular endothelial growth factor (VEGF). Treatment with simvastatin resulted in a significant reduction in the frequency of pain (P = 0·0003), oral analgesic use (P = 0·003) and circulating hs-CRP (P = 0·003), soluble (s)E-selectin (P = 0·01), sICAM-1 (P = 0·02), sICAM-3 (P = 0·02) and sVEGF (P = 0·01). Simvastatin had no effect on pain intensity or levels of NOx, sP-selectin and sVCAM-1. The observed reductions in pain rate and markers of inflammation were greatest in subjects receiving hydroxycarbamide (HC), suggesting a synergistic effect of simvastatin. These results provide preliminary clinical data to support a larger trial of simvastatin in SCA.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hoppe C, Jacob E, Styles L, et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017. PMID: 28369718. doi:10.1111/bjh.14580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。